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Abstract
COPD induced following biomass smoke exposure has been reported to be associated with a more fibrotic phenotype than
cigarette smoke induced COPD. This study aimed to investigate if biomass smoke induced extracellular matrix (ECM) protein
production from primary human lung fibroblasts in vitro. Primary human lung fibroblasts (n = 5–10) were stimulated in vitro
for up to 72 hours with increasing concentrations of biomass smoke extract (BME) or cigarette smoke extract (CSE) prior to
being assessed for deposition of ECM proteins, cytokine release, and activation of intracellular signalling molecules.
Deposition of the ECM proteins perlecan and fibronectin was upregulated by both CSE (p,0.05) and BME (p,0.05). The
release of the neutrophilic chemokine IL-8 was also enhanced by BME. ERK1/2 phosphorylation was significantly
upregulated by BME (p,0.05). Chemical inhibition of ERK signalling molecules partially attenuated these effects (p,0.05).
Stimulation with endotoxin had no effect. This study demonstrated that BME had similar effects to CSE in vitro and had the
capacity to directly induce fibrosis by upregulating production of ECM proteins. The mechanisms by which both biomass
and cigarette smoke exposure cause lung damage may be similar.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a leading
cause of death worldwide, most commonly caused in developed
countries by cigarette smoking. Although the link between
cigarette smoking and COPD is well founded, epidemiological
studies have demonstrated that a substantial proportion of patients
with COPD worldwide are never smokers. [1] A growing body of
evidence has demonstrated that exposure to smoke from the
burning of biomass fuels may be a critical risk factor for the
development of COPD in non smokers. [2]
Biomass fuels such as firewood, animal manure and coal are
commonly used for heating and cooking around the world. It is
estimated that 3 billion people are exposed to indoor smoke from
the burning of biomass fuels. [3] Women who cook with biomass
fuels are more likely to report respiratory symptoms of cough and
wheeze, and have poorer lung function compared to women who
do not use biomass fuels for cooking. [4]
Biomass smoke exposure has a similar association with the
development of COPD as cigarette smoking, [5] with biomass
exposure estimated to increase the risk of developing COPD by
2.4 times. [6] Pathological features of biomass smoke induced
COPD include bronchial anthracofibrosis, [7] small airway disease
[8] and chronic bronchitis. [5] Biomass exposure can lead to both
restrictive and obstructive effects on breathing, with the most
commonly reported change in lung function in those exposed to
biomass exposure being a decline in forced expiratory volume in 1-
second (FEV1). [1,5,8]
Extensive imaging [9,10] and histological [11] studies have
demonstrated that thickening of the small airway walls is the major
contributing factor in COPD to the decline in FEV1. In COPD,
thickening of the airway wall is characterised by increased fibrotic
deposition of extracellular matrix (ECM) proteins, [12] vascular-
isation [13] and thickening of the epithelial layer. [11] Thickened
airways have been observed during autopsies of subjects with
significant biomass smoke exposure, where significant airway
fibrosis was observed in both the large and the small airways and
the extent of fibrosis exceeded that of those of cigarette smokers.
[14] Therefore, the decline in FEV1 associated with biomass
smoke exposure [1,5,8] may be due to biomass smoke exposure
causing airway thickening.
Biomass smoke is composed of over 200 different compounds,
many of which can be inhaled into the small airways. [3] It
contains particulate matter, carbon monoxide, polyaromatic
hydrocarbons, free radicals, high levels of endotoxin, [15] and
many other volatile organic compounds. [16] Although biomass
smoke exposure is a considerable risk factor for the development of
COPD in non smokers, very little research has been undertaken to
determine the mechanisms by which biomass smoke exposure
leads to detrimental changes in lung function.
This study aimed to investigate the effect of biomass smoke
exposure on human lung cells in vitro, specifically examining
biomass smoke on markers of airway remodelling, such as
deposition of ECM proteins and cytokine release, to demonstrate
that biomass smoke exposure can directly cause changes that may
relate to airway remodelling, and thus the decline in FEV1 in vivo.
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Methods
Ethics statement
Human airway tissue was obtained from explanted and resected
lungs and post mortem organ donors with ethical approval from
The University of Sydney and participating hospitals (Concord
Repatriation General Hospital, Sydney South West Area Health
Service and Royal Price Alfred Hospital) for sample collection. All
volunteers, or their next of kin, provided written informed consent.
Chemicals
The following chemicals were obtained from the companies
indicated:
DMEM, dimethyl sulfoxide (DMSO), BSA, ammonium hy-
droxide, Direct red 80, Picric Acid (Sigma, St Louis, MI), PBS,
penicillin, streptomycin, amphotericin B (Invitrogen, Carslbad,
CA), FBS (Bovogen, East Keilor, Australia), UO126, PD98059
(Calbiochem, San Diego, CA).
Fibroblast isolation
Approval for all experiments with human lung was provided by
the Human Ethics Committees of The University of Sydney and
the Sydney South West Area Health Service. Human lung
fibroblasts were isolated from lung tissue obtained from donors
undergoing resection for thoracic malignancies or lung transplan-
tation and they gave written, informed consent. Donor character-
istics, where available, were obtained with permission, from the
patient’s medical records post-surgery. Disease diagnosis was made
by a physician according to current guidelines. We were unable to
obtain data on donor’s exposure to environmental pollution or
biomass smoke prior to sample collection. Characteristics of the
donors, including age, smoking status, pack years and lung
function, are provided in table 1. Human lung fibroblasts were
isolated from distal small airways as previously published [17]. To
obtain human lung fibroblasts, cells were obtained from proximal
lung tissue containing small airways (,1 mm) which were deemed
to be free of tumour following pathological examination. This
tissue was minced in 1–2 mm pieces into sterile Hanks Buffered
Saline Solution (Hanks) and centrifuged for 5 minutes at
1000 rpm. Supernatant was aspirated and the tissue pellet was
resuspended and plated onto tissue culture grade plastic flasks in
10% (vol/vol) FBS/2% antibiotics/DMEM.
The lung fibroblasts proceeded to grow out of the tissue
fragments to form a monolayer covering of the tissue culture flasks.
Once the monolayer of cells was confluent, the cells were
passaged. All experiments were carried out using cells between
passage 3 and 6.
In preparation for in vitro experimentation, cells were seeded in
96 &/or 12 well plates for 72 hours in 5% (vol/vol) FBS/
antibiotics/DMEM at a density of 16104 cells/cm2. Cells were
equilibrated before experimental stimulation for 24 hours in 0.1%
(vol/vol) FBS/antibiotics/DMEM.
Cell culture
Human lung fibroblasts were seeded at a density of
3.26104 cells/cm2 in 5% FBS/antibiotics/DMEM for 72 hours.
Cells were then equilibrated by incubation in 0.1% FBS/
antibiotics/DMEM for 24 hours prior to stimulation.
Biomass smoke extract preparation
Biomass smoke extract (BME) was prepared fresh by combust-
ing 500 mg of biomass (Quercus robur (English Oak)) and bubbling
through 25 ml DMEM. This solution, 100% BME, was then
diluted in 0.1% (vol/vol) FBS/antibiotic/DMEM and applied to
cells within 30 minutes of preparation.
Fibroblasts were incubated with 1%, 5%, 10% and 20% BME in
0.1% FBS/antibiotics/DMEM for 72 hours before supernatants
were collected and cell deposited ECM was exposed. The ECM was
exposed by first washing the cells in PBS, before cells were lysed by
exposure to 0.1 M NH4OH (Worsley Alumina, WA, Australia) for
15 minutes. Plates were then washed three additional times in PBS
to remove cell debris, as previously described. [17] Smoke exposed
and smoke naı̈ve cells were cultured in separate, isolated incubators
to prevent smoke extract ‘leaching’ across into naı̈ve cells.
Cigarette smoke extract preparation
Cigarette smoke extract (CSE) was prepared as previously
described. [17] Briefly, the smoke from one commercial, high-tar
cigarette was bubbled through 25 ml DMEM to make a 100%
CSE solution.
Particle concentration analysis
Analysis of the relative quantities of particulate matter in the
smoke generated by burning biomass and cigarettes were assessed
using a Lasair II laser particle counter (Particle Measurement
Systems, Boulder, CO) which samples particle sizes in the ranges
of 0.3–0.5, 0.5–1, 1.0–5, 5–10, 10–25 and .25 mm. One litre of
freshly generated smoke was diluted into 39 litres of medical grade
N2 gas, of which 28.31 litres was sampled to give a total particle
count from which values of particles per m3 were calculated.
Experiments were performed in triplicate.
Assessment of endotoxin levels and pH
Relative levels of endotoxin in BME and CSE were assessed
using a commercially available limulus amebocyte lysate (LAL)
assay according to the manufacturer’s instructions (Cape Cod,
East Falmouth, MA). Briefly, the quantity of lipopolysaccharide
(LPS) contained in BME and CSE was measured in duplicate
using 1:10, 1:100 and 1:1000 dilutions of each sample made with
pyrogen-free water using a chromogenic LAL assay with b-glucan
inhibiting buffer and a standard curve with a sensitivity range of
0.008 - 2 EU/ml. To evaluate possible sample interference with
LPS measurements, additional duplicates of each sample were
spiked with LPS added directly to the assay well. Total LPS
bioactivity was measured by kinetic assay using a VersaMax
microplate reader with SoftMax Pro 5 software.
The pH of samples was measured electronically using a
calibrated Cyberscan 500 pH probe (ThermoFisher Scientific).
Growth factor stimulation
In addition to BME and CSE exposure, in some experiments
cells were stimulated with 1 ng/ml recombinant human TGF-b1
(R&D Systems, Minneapolis, MN) or 0.05, 0.5 and 5 mg/mL
purified LPS, a major component in endotoxin, as control stimuli.
Cytotoxicity assay
Cytotoxicity was assessed by trypan blue exclusion, a commer-
cially available lactate dehydrogenase (LDH) assay and a
commercially available 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyl-
tetrazolium Bromide (MTT) assay according to the manufacturer’s
instructions (Sigma).
Extracellular matrix ELISA
Relative levels of fibronectin and perlecan deposited into the
ECM were assessed by an ECM ELISA. Briefly, cells were washed
in PBS, and then lysed using 0.1 M NH4OH (Worsley Alumina,
Biomass Smoke
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WA, Australia) for 15 minutes. Plates were then washed three
additional times to remove cell debris. Deposition of proteins into
the ECM was measured using 4 mg/ml mouse-anti fibronectin C-
terminal (Chemicon, Billerica, MA) antibodies and 2 mg/ml
mouse anti-perlecan antibodies in 1% BSA/PBS as previously
published.[17]
Signalling pathways - Analysis of ERK activation by
western blotting
To assess the activation of intracellular signalling molecules in
fibroblasts following stimulation with BME or CSE, relative levels
of extracellular regulated kinase (ERK)/1 and ERK/2 phosphor-
ylation from cell lysates collected after 10, 20, and 30 minutes
stimulation with BME or CSE was assessed by western blotting.
Briefly,lysates were diluted in a 5x SDS-PAGE sample buffer,
denatured, separated by polyacrylamide (10%) gel electrophoresis
and then transferred onto a polyvinylidene difluoride (PVDF)
membrane (Millipore). Following protein transfer, non specific
binding was blocked via incubation of the membrane for 1 hour
with 5% BSA (w/v). Mouse anti-phospho-ERK/1 and phospho-
ERK/2 antibodies (Cell signalling) were used to identify phospho-
ERK/1 and phospho-ERK/2 respectively, which were detected
using luminescence via secondary HRP conjugated anti-mouse
antibodies (Dako, Glostrup, Denmark) and SuperSignal lumines-
cence buffer (Gibco), using a Kodak Image Station Camera and
software. The membranes were then stripped using stripping
buffer (0.063 mM Tris, pH 6.8, 2% SDS, 0.7% b-mercaptoeth-
anol) and reincubated with 0.002 ng/ml mouse anti-glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) monoclonal antibody
(Chemicon, Millipore, Temecula, CA) after blocking.
ECM ELISA
Fibroblasts were treated with or without the ERK MAPK
inhibitors UO126 or PD98059 in appropriate concentrations of
DMSO in 0.1% FBS/antibiotics/DMEM. After one hour, media
was aspirated before the addition of 1%, 5%, 10% and 20% BME
or 5% CSE in the presence of inhibitors for 72 hours. Following
stimulation, relative levels of fibronectin and perlecan deposited
into the ECM were assessed by an ECM ELISA and levels of IL-8
released into the supernatant were assessed by ELISA.
IL-8 ELISA
Levels of IL-8 released into the supernatant following stimula-
tion with 1%, 5%, 10% and 20% BME for 72 hours were assessed
Table 1. Characteristics of fibroblasts donors.





1 59 F Carcinoma R No 93 79 0.94
2 73 M NSCLC R ex 59 51 0.93
3 45 F COPD T ex N/A N/A N/A
4 60 M Bronchiectasis T N/A 22 64 0.51
5 54 F Ca + COPD R ex 73 93 0.63
6 59 M COPD T ex 11 52 0.17
7 69 M NSCCa + COPD R ex 56 59 0.75
8 67 M NSCLC R ex 103 101 0.79
9 71 M NSCLC R No 93 89 0.79
10 72 M NSCLC R ex 83 89 0.73
11 60 F NSCLC R ex 99 107 0.79
12 60 M IPF T N/A N/A N/A N/A
13 74 F NSCLC R N/A N/A N/A N/A
14 53 M Mass + Pneumonia R N/A N/A N/A N/A
15 75 M NSCLC R N/A N/A N/A N/A
16 64 M Carcinoma R ex 93 95 0.97
17 57 M Sarcoidosis R N/A 56 60 0.72
18 73 M NSCLC + COPD R ex 67 73 0.73
19 69 F NSCLC R N/A N/A N/A N/A
20 74 F COPD T ex 64 55 0.93
21 63 M COPD T ex N/A N/A N/A
22 72 F NSCLC R N/A N/A N/A N/A
23 61 M COPD T ex 13 47 0.23
24 43 F COPD T ex N/A N/A N/A
25 60 F Carcinoma R ex 101 92 0.86
26 56 M COPD T ex 14 35 0.31
Lung function data presented as % of predicted values for donor’s gender, age and height. F: Female, M: Male, NSCLC: non small cell lung carcinoma, COPD: chronic
obstructive pulmonary disease, Ca: carcinoma, IPF: idiopathic pulmonary fibrosis, R: resection, T: Transplant. FEV1 forced expiratory volume in 1 second. FVC: forced vital
capacity. N/A: data not available.
doi:10.1371/journal.pone.0083938.t001
Biomass Smoke
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using commercial antibody kits according to the manufacturer’s
instructions (R&D Systems).
Data analysis
ECM protein deposition was corrected by subtracting the
absorbance reading of ‘‘no-cell’’ negative control wells from the
fibroblast containing wells to remove background absorbance. All
data were collated using Microsoft Excel Software and analysed
using GraphPad Prism 5.0 (GraphPad, La Jolla, CA). Differences
were considered to be significant when p,0.05.
Results
Analysis of BME and CSE
The mean endotoxin level in CSE was 4.2362.08 EU/ml,
whilst BME contained 2.6060.59 EU/ml, and these values where
not significantly different. The pH of 100% BME (7.8460.01) was
slightly higher than 100% CSE (7.5760.01) and 0.1% FBS/
antibiotics/DMEM (7.5760.03), indicating a slightly more alka-
line solution. However, when the BME was diluted in 0.1% FBS/
antibiotics/DMEM to the concentrations used in the experiments,
the pH of 20% BME was 7.59 (60.04) and 10% BME was 7.56
(60.02).
Both biomass smoke and cigarette smoke contained very high
levels of small particles,with biomass smoke containing an average
of 3.056109 particles/m3 in the 0.3–10 mm size range and
cigarette smoke containing an average of 2.936109 particles/m3
of the same size range (Figure 1 A, B). Biomass and mainstream
cigarette smoke contained similar proportions of small particles,
respectively yielding 92.0% and 95.6% of total particles in the 0.3–
10 mm size range (Figure 1C, D).
High concentrations of biomass extract are cytotoxic
We initially assessed cytotoxicity of 1, 5, 10 and 20% BME via
the LDH assay (Figure 2A). The data suggested that BME was not
cytotoxic to fibroblasts (n = 3) following 72 hours stimulation. As
we had previously observed that high concentrations of CSE were
cytotoxic [17], this was an unexpected result. We then assessed the
effect of BME on cell viability using a MTT assay (Figure 2B). The
data also suggested that BME did not have a significant effect on
cell viability (n = 3). We then performed manual cell counts after
72 hours stimulation and these data demonstrated that the
stimulation with 1, 5 and 10% BME did not significantly alter
the total cell number (Figure 2C), however the number of viable
cells present after 72 hours stimulation with 20% BME was
significantly decreased compared to controls (p,0.05, n = 6).
Biomass extract enhances deposition of fibronectin
As fibronectin is a significant component of the ECM [18] and
is upregulated in COPD, [12] we assessed the deposition of
fibronectin from human lung fibroblasts using an ECM ELISA.
We found that fibronectin deposition was significantly increased
following 72 hours stimulation with 5% CSE, 10% and 20% BME
(p,0.05, n = 16) (Figure 3A).
Figure 1. Biomass smoke and cigarette smoke have similar particle consistency. Quantity and distribution of particles from the smoke of
one cigarette (A) or one unit of biomass (B) as measured by laser particle counter. Data expressed as particles per cubic metre or as % of total particle
counts (C–D) for particles in the size ranges of 0.3–0.5, 0.5–1, 1–5, 5–10, 10–25 or ,25 uM diameter. Bars represent mean 6 SEM. Each experiment
was performed in triplicate.
doi:10.1371/journal.pone.0083938.g001
Biomass Smoke
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Deposition of the glycosaminoglycan, perlecan, was not altered
by stimulation with BME (n = 6)(Figure 3B).
Chemical inhibitors of ERK MAPK attenuate biomass-
induced fibronectin deposition
The deposition of fibronectin induced by 20% BME was
significantly attenuated following 72 hours stimulation in the
presence of both ERK inhibitors PD98059 and UO126 (p,0.05
vs vehicle control, n = 5) (Figure 4B and 4D).
Biomass extract enhances release of IL-8
As neutrophilic inflammation is a characteristic feature of
COPD, we sought to assess the effect of BME on release of the
chemotactic cytokine IL-8 by human lung fibroblasts.
Our data demonstrated that after 72 hours stimulation, 10%
and 20% BME significantly upregulated the release of IL-8 into
the supernatant compared to control (p,0.05, n = 10) (Figure 5).
In cells stimulated in the presence of the ERK inhibitors PD98059
(10 mM, 1 mM) and UO126 (5 mM, 0.5 mM), the release of IL-8
induced by 10% BME, but not 20% BME, was significantly
attenuated by the higher concentrations of PD98059 and UO126
(p,0.05, n = 5) (Figure 6).
Biomass extract enhances phosphorylation of ERK
As the ERK MAPK signalling pathway has been previously
demonstrated to be activated by particulate matter [19] we
assessed the phosphorylation of ERK1/2 by BME in human lung
fibroblasts via western blotting. Compared to time 0, BME began
to increase pERK1/2 after 30 minutes in a dose-related fashion.
Following two hours stimulation, pERK1/2 was significantly
increased, compared to control, by 5% and 20% BME (p,0.05,
n = 6) (Figure 7). Whilst pERK1 levels decreased by 24 hours,
pERK2 remained significantly increased by 10% and 20% BME
(p,0.05, n = 6) (data not shown).
LPS does not increase fibronectin deposition or IL-8
release from human lung fibroblasts
As LPS is a major component of endotoxin, which we found to
be present in BME, we tested the direct effects of LPS on
fibronectin deposition or the release of IL-8 from human lung
fibroblasts. The profibrotic cytokine TGF-b1 (1 ng/ml), used as a
positive control, increased fibronectin deposition as measured by
Figure 2. High concentrations of biomass smoke are cytotoxic.
Assessment of cytotoxicity of biomass smoke extract (BME) to human
lung fibroblasts (n = 3) as measured by LDH assay (A), MTT assay (B) or
manual cell counts (C) following stimulation with 5% cigarette smoke
extract (CSE) or 1, 5, or 20% BME in 0.1% FBS/DMEM. Data expressed as
% of unstimulated. Bars represent mean 6 SEM. Data analysed by one-
way ANOVA with Dunnet’s post test.*p,0.05 vs unstimulated, n = 6.
doi:10.1371/journal.pone.0083938.g002
Figure 3. Biomass smoke extract enhances deposition of
fibronectin from fibroblasts. Deposition of fibronectin (n = 16) (A)
or perlecan (n = 6) (B) from human lung fibroblasts as measured by ECM
ELISA following 72 hours stimulation with 5% cigarette smoke extract
(CSE) or 1, 5, 10 or 20% biomass smoke extract (BME) in 0.1% FBS/
DMEM. Data expressed as absorbance at 405 nm with media alone
baseline removed (A,B). Bars represent mean 6 SEM. Data analysed by




PLOS ONE | www.plosone.org 5 December 2013 | Volume 8 | Issue 12 | e83938
ECM ELISA (p,0.05, n = 5) (Figure 8A). In comparison,
stimulation for 72 hours with 0.05, 0.5 and 5 mg/ml LPS did
not alter the deposition of fibronectin from human lung fibroblasts.
The release of IL-8 from human lung fibroblasts was also not
enhanced following stimulation with LPS (Figure 8B) and whilst
not statistically significant, LPS appeared to attenuate constitutive
IL-8 release after 72 hours.
Discussion
This study has demonstrated that biomass smoke extract can
directly upregulate the deposition of the ECM protein fibronectin
and release of the neutrophil attractant chemokine IL-8 from
human lung fibroblasts, through a process which may involve
activation of the ERK signalling pathway.
As increased matrix deposition is a characteristic of airway
remodelling, the pathological changes observed in biomass smoke
Figure 4. Chemical inhibition of the ERK signalling pathway attenuates biomass smoke induced fibronectin deposition. Fibroblasts
were pretreated for 1 hour with the ERK inhibitors PD98059 (10 mM) (A,B) or UO126 (5 mM) (C,D) in DMSO (vehicle control) before stimulation with
10% (A,C) and 20% BME (B,D) in the presence of inhibitors for 72 hours, prior to analysis of fibronectin deposition by ECM ELISA. Data expressed as %
of unstimulated. Bars represent mean 6 SEM. Data analysed by T-Test. *p,0.05 vs vehicle control, n = 5.
doi:10.1371/journal.pone.0083938.g004
Biomass Smoke
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induced COPD in vivo may be, in part, due to direct upregulation
of matrix proteins. Thus the decline in FEV1 observed in those
exposed to biomass smoke may be due to airway remodelling and
inflammation which has occurred as a result of biomass smoke
exposure.
We found that BME activates the ERK signalling pathway and
that the release of IL-8 and deposition of fibronectin were partially
attenuated by chemical inhibition of this pathway. ERK has been
shown to be activated by CSE in human lung fibroblasts, [20]
airway epithelial cells [21] and immune cells. [22] In studies of
COPD, ERK can be activated by the nicotine contained in
cigarette smoke [23] and ERK is linked to inflammation, [24,25]
enhanced airway smooth muscle proliferation [26] and mucin
production. [27]
Whilst chemically inhibiting the ERK pathway did not
completely attenuate the effects of BME, we and others have
demonstrated the involvement of nuclear factor kappa-B (NF-kB),
janus regulated kinase (JNK) and Smad signalling pathways in
fibronectin deposition and IL-8 release. [17,28–32] Thus it is
reasonable to conclude that whilst ERK activation plays a
significant role in BME induced fibronectin deposition and IL-8
release, other signalling molecules are likely to be involved.
Fibronectin is an important component of the ECM that has
been demonstrated to play an active role in the pathogenesis of
lung disease. Enhanced expression of fibronectin has been
observed in COPD [12] and in the bronchial alveolar lavage
fluid from smokers. [33] In addition fibroblasts from patients with
idiopathic pulmonary fibrosis [34] and COPD [17] produce more
fibronectin than controls, suggesting a role of this molecule in
fibrosis. We have previously demonstrated that CSE can directly
upregulate fibronectin deposition from fibroblasts, [17] whilst
others have shown that fibronectin is enhanced by nicotine,
[28,35] ethanol, [36] TGF-b1, [37] oxidative stress [38] and
mechanical strain. [39] Fibronectin is critically involved in wound
repair processes in the lung, and enhanced levels of fibronectin
may promote fibrosis. Reduced fibronectin levels can directly
diminish the rate of wound closure of airway epithelial cells [40]
and fibronectin knock-out mice fail to develop fibrosis in response
to bleomycin. [41] Fibronectin directly mediates and enhances
migration of small airway and alveolar epithelial cells, [42,43] and
also enhances proliferation of lung carcinoma cells [44] and
airway smooth muscle cells. [45–47] Whilst there have not been
detailed immunohistochemical analyses of airways of persons who
develop biomass smoke induced COPD, we demonstrate in vitro
that BME has the capacity to enhance the deposition of
fibronectin. Future studies are warranted to determine if this
observation correlates to the pathology of airway remodelling in
vivo.
Neutrophilic inflammation is a hallmark characteristic of
COPD. [48] Interleukin 8 is the main chemotactic mediator for
neutrophils, having been established as the key mediator driving
neutrophilic inflammation in vitro and in vivo. [49,50] IL-8 is of
interest in COPD as patients with COPD have more IL-8 in both
sputum and serum than asthmatics or healthy controls. [51]
Concurrently, they also have greater numbers of neutrophils in
sputum. [52] In patients with COPD, a significant inverse
Figure 5. Biomass smoke exposure upregulates release of IL-8
from fibroblasts. Release of interleukin (IL)-8 from human lung
fibroblasts (n = 10) in response to 72 hours stimulation with 1, 5, 10 or
20% biomass smoke extract (BME) in 0.1% FBS/DMEM as measured by
IL-8 ELISA. Data expressed as pg/ml. Bars represent mean 6 SEM. Data
analysed by one-way ANOVA with Dunnet’s post-test. *p,0.05 vs
unstimulated, n = 10.
doi:10.1371/journal.pone.0083938.g005
Figure 6. Chemical inhibition of the ERK signalling pathway
attenuates BME induced IL-8 release. Fibroblasts were pretreated
for 1 hour with the ERK inhibitors PD98059 (1, 10 mM) or UO126 (0.5,
5 mM) in DMSO (vehicle control) before stimulation with 10% (A) and
20% (B) BME in the presence of inhibitors for 72 hours, prior to analysis
of IL-8 release by ELISA. Data expressed as pg/ml. Bars represent mean
6 SEM. Data analysed by one-way ANOVA with Bonferroni’s post-
test.*p,0.05 vs vehicle control, n = 5.
doi:10.1371/journal.pone.0083938.g006
Biomass Smoke
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correlation has been observed between levels of IL-8 in the
epithelial layer and FEV1. [53] Thus by enhancing the release of
IL-8, biomass smoke may mediate the recruitment of neutrophils
which in turn can release inflammatory mediators and proteolytic
enzymes, thus having an active role in the progression of
obstructive lung disease.
The deposition of perlecan was not upregulated by BME in this
study. We previously demonstrated that the deposition of
fibronectin and perlecan following CSE exposure involved
different signalling pathways. [17] Specifically CSE induced
fibronectin involved the NF-kB pathway, whilst CSE induced
perlecan involved the activation of the Janus Kinase (JAK)/Stat
pathway. A possible mechanism for the upregulation of fibronec-
tin, but not perlecan, observed in this study may be that BME does
not activate the JAK/Stat signalling pathway. A limitation of our
study is that we did not examine the activation of this pathway, so
further research on the mechanisms by which fibronectin is
upregulated is warranted.
Whilst endotoxin is a substantial component of BME, the direct
stimulation of human lung fibroblasts with LPS failed to induce
similar changes to those observed when cells were directly
stimulated with BME. This finding demonstrates that the increase
in fibronectin deposition and IL-8 observed are not solely due to
the presence of endotoxin.
We were not able to ascertain the molecules present in BME
responsible for the observed changes in this study as biomass
smoke contains over 200 different compounds. Likely candidates
may be polyaromatic hydrocarbons [54] or particulate matter such
as PM2.5 itself. [55] Particulates ,10 uM in diameter may drive
the harmful effects of inhaled substances on the respiratory system.
[56] This study demonstrated similar particulate profiles between
biomass and cigarette smoke, with the majority of particles being
Figure 7. BME activates ERK1/2 signalling molecules. Fibroblasts
were stimulated for 2 hours with 5% CSE or 1, 5, 10 or 20% BME in 0.1%
FBS/DMEM, before whole cell lysates were collected and ERK1 (A) or
ERK/2 (B) phosphorylation was assessed by western blotting. Data
expressed as the ratio of pERK over GAPDH (housekeeping protein).
Bars represent mean 6 SEM. Data analysed by one-way ANOVA with
Dunnet’s post-test *p,0.05 vs unstimulated, n = 5. Image at top of
graph is a representative composite western blot.
doi:10.1371/journal.pone.0083938.g007
Figure 8. LPS does not induce fibronectin deposition (A) or IL-8
release (B). Human lung fibroblasts were stimulated for 72 hours with
0.05, 0.5 or 5 mg/ml lipopolysaccharide (LPS) prior to analysis of
fibronectin deposition by ECM ELISA (A) or IL-8 release by ELISA (B). The
profibrotic cytokine TGF-b1 (1 ng/ml) was used as a positive control for
fibronectin deposition. Data expressed as % of unstimulated (A) or pg/
ml (B). Bars represent mean 6 SEM. Data analysed by one-way ANOVA
with Dunnet’s post-test.*p,0.05 vs unstimulated, n = 5.
doi:10.1371/journal.pone.0083938.g008
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in the 0.5–10 uM range for both substances. Therefore, as both
biomass and cigarette smoke have similar particulate profiles, it is
reasonable to conclude that exposure to biomass smoke may
induce similar pathological effects as cigarette smoke, and this may
reflect the similarity in particle size of both stimuli.
A recent study demonstrated LPS directly induced IL-8 from
human lung fibroblasts after 24 hours, [57] a finding which
contrasts our study, whereby LPS did not induce IL-8 release at
72 hours. Whilst the differences may be due to the time points
examined and the cell culture conditions, further research on the
influence of endotoxin on cellular physiology is warranted.
Biomass smoke exposure has an enormous impact on health in
developing areas, contributing greatly to morbidity and mortality.
[2] Whilst priority needs to be given to interventions to reduce
biomass smoke exposure, further research is also needed to better
characterise both the mechanisms and pathology of biomass
smoke induced lung disease, so as to enable better therapeutic
options for those who have already had substantial exposure.
In conclusion, we have demonstrated that exposure to biomass
smoke in vitro can enhance the deposition of a key ECM protein
and the release of a major neutrophilic chemotactic mediator from
human lung fibroblasts, via the activation of the ERK signalling
pathway. These findings provide a novel mechanism for lung
injury following biomass smoke exposure.
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